Short Interest in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Grows By 330.5%

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) was the target of a significant increase in short interest during the month of June. As of June 15th, there was short interest totaling 16,744 shares, an increase of 330.5% from the May 31st total of 3,889 shares. Currently, 9.8% of the company’s shares are sold short. Based on an average trading volume of 2,088 shares, the short-interest ratio is presently 8.0 days.

Institutional Investors Weigh In On Amplify Weight Loss Drug & Treatment ETF

An institutional investor recently raised its position in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC increased its holdings in shares of Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) by 5.1% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,891 shares of the company’s stock after buying an additional 1,215 shares during the period. Jane Street Group LLC owned 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 at the end of the most recent quarter.

Amplify Weight Loss Drug & Treatment ETF Price Performance

Shares of THNR stock opened at $25.36 on Monday. The firm has a market cap of $4.31 million, a price-to-earnings ratio of 24.31 and a beta of 0.40. Amplify Weight Loss Drug & Treatment ETF has a 12 month low of $21.70 and a 12 month high of $27.28. The stock has a 50-day moving average price of $24.50 and a 200 day moving average price of $25.10.

Amplify Weight Loss Drug & Treatment ETF Company Profile

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.